ABSTRACT:Human CYP1A2 is an important drug-metabolizing enzyme, similar in sequence to CYP1A1 but with distinct substrate specificity. We have previously shown that residue 382 affected CYP1A1 and CYP1A2 specificities with alkoxyresorufins. To determine whether this residue is also important for the metabolism of other substrates, we have investigated phenacetin oxidation by single (T124S, T223N, V227G, N312L, and L382V) and multiple (L382V/ T223N, L382V/N312L, L382V/T223N/N312L, and L382V/T124S/ N312L) mutants of CYP1A2. The enzymes were expressed in Escherichia coli and purified. All the CYP1A2 mutants that contained the L382V substitution displayed much higher activities than the wildtype enzyme, with k cat values 3-fold higher, in contrast to other mutants, for which k cat decreased. Likewise, a significant increase in specificity, expressed as the k cat /K m ratio, was observed for the mutants containing the L382V substitution. The efficiency of coupling of reducing equivalents to acetaminophen formation was decreased for all the single mutants except L382V, for which the coupling increased. This effect was also observed with multiple CYP1A2 mutants containing the L382V substitution. Low activities of the four other single mutants were likely caused by dramatically increased uncoupling to water. In contrast, the increase in activity of the L382V-containing mutants resulted from decreased water formation. This finding is consistent with molecular dynamics results, which showed decreased phenacetin mobility leading to increased product formation. The results of these studies confirm the importance of residue 382 in CYP1A2-catalyzed oxidations and show that a single residue substitution can dramatically affect enzymatic activity.Cytochromes P450 (P450s) are heme-containing monooxygenase enzymes, which are involved in the metabolism of numerous exogenous and endogenous compounds. P450s are ubiquitous in living organisms, with at least 50 families and 82 subfamilies found in different species. Human CYP1A subfamily has two major isoforms: CYP1A1 and CYP1A2. CYP1A2, one of the major P450s in the human liver, was first characterized as a phenacetin O-deethylase (Distlerath et al., 1985). Currently, it is estimated that this enzyme metabolizes approximately 11% of all drugs in humans (Shimada et al., 1994). Despite the fact that CYP1A2 participates in the deactivation and detoxification of xenobiotics, the main interest in this enzyme is because of the metabolic activation of a large number of chemical carcinogens (Guengerich and Shimada, 1991;Lewis et al., 1994).In humans, CYP1A2 shares 72% amino acid sequence identity with CYP1A1, but the substrate specificities and inhibitor susceptibilities of these enzymes are different. For example, substrates such as phenacetin and 7-methoxyresorufin are primarily metabolized by CYP1A2 with high catalytic efficiency, whereas CYP1A1 displays weak capability to oxidize those substrates. On the other hand, 7-ethoxyresorufin is preferentially oxidized by CYP1A1 (Nerurkar et al.,...